|
1
|
Ferlay J, Shin HR, Bray F, Forman D,
Mathers C and Parkin DM: Estimates of worldwide burden of cancer in
2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar
|
|
2
|
Enzinger PC and Mayer RJ: Esophageal
cancer. N Engl J Med. 349:2241–2252. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lepage C, Rachet B, Jooste V, Faivre J and
Coleman MP: Continuing rapid increase in esophageal adenocarcinoma
in England and Wales. Am J Gastroenterol. 103:2694–2699. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Pennathur A, Farkas A, Krasinskas AM,
Ferson PF, Gooding WE, Gibson MK, Schuchert MJ, Landreneau RJ and
Luketich JD: Esophagectomy for T1 esophageal cancer: Outcomes in
100 patients and implications for endoscopic therapy. Ann Thorac
Surg. 87:1048–1054; discussion 1054–1055. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ito T, Shimada Y, Hashimoto Y, Kaganoi J,
Kan T, Watanabe G, Murakami Y and Imamura M: Involvement of TSLC1
in progression of esophageal squamous cell carcinoma. Cancer Res.
63:6320–6326. 2003.PubMed/NCBI
|
|
6
|
Qian H, Lu N, Xue L, Liang X, Zhang X, Fu
M, Xie Y, Zhan Q, Liu Z and Lin C: Reduced MTA1 expression by RNAi
inhibits in vitro invasion and migration of esophageal squamous
cell carcinoma cell line. Clin Exp Metastasis. 22:653–662. 2005.
View Article : Google Scholar
|
|
7
|
De Wever O, Pauwels P, De Craene B, Sabbah
M, Emami S, Redeuilh G, Gespach C, Bracke M and Berx G: Molecular
and pathological signatures of epithelial-mesenchymal transitions
at the cancer invasion front. Histochem Cell Biol. 130:481–494.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ruiz P and Günthert U: The cellular basis
of metastasis. World J Urol. 14:141–150. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Boyer B, Vallés AM and Edme N: Induction
and regulation of epithelial-mesenchymal transitions. Biochem
Pharmacol. 60:1091–1099. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Birchmeier C, Birchmeier W and
Brand-Saberi B: Epithelial-mesenchymal transitions in cancer
progression. Acta Anat (Basel). 156:217–226. 1996. View Article : Google Scholar
|
|
11
|
Cavallaro U, Schaffhauser B and
Christofori G: Cadherins and the tumour progression: Is it all in a
switch? Cancer Lett. 176:123–128. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Huber MA, Kraut N and Beug H: Molecular
requirements for epithelial-mesenchymal transition during tumor
progression. Curr Opin Cell Biol. 17:548–558. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Tomita K, van Bokhoven A, van Leenders GJ,
Ruijter ET, Jansen CF, Bussemakers MJ and Schalken JA: Cadherin
switching in human prostate cancer progression. Cancer Res.
60:3650–3654. 2000.PubMed/NCBI
|
|
14
|
Nakajima S, Doi R, Toyoda E, Tsuji S, Wada
M, Koizumi M, Tulachan SS, Ito D, Kami K, Mori T, et al: N-cadherin
expression and epithelial-mesenchymal transition in pancreatic
carcinoma. Clin Cancer Res. 10:4125–4133. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Derycke LD and Bracke ME: N-cadherin in
the spotlight of cell-cell adhesion, differentiation,
embryogenesis, invasion and signalling. Int J Dev Biol. 48:463–476.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Shintani Y, Hollingsworth MA, Wheelock MJ
and Johnson KR: Collagen I promotes metastasis in pancreatic cancer
by activating c-Jun NH(2)-terminal kinase 1 and up-regulating
N-cadherin expression. Cancer Res. 66:11745–11753. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Richmond HG: Induction of sarcoma in the
rat by iron-dextran complex. BMJ. 1:947–949. 1959. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Okada S, Hamazaki S, Toyokuni S and
Midorikawa O: Induction of mesothelioma by intraperitoneal
injections of ferric saccharate in male Wistar rats. Br J Cancer.
60:708–711. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hann HW, Stahlhut MW and Blumberg BS: Iron
nutrition and tumor growth: Decreased tumor growth in
iron-deficient mice. Cancer Res. 48:4168–4170. 1988.PubMed/NCBI
|
|
20
|
Ohara T, Noma K, Urano S, Watanabe S,
Nishitani S, Tomono Y, Kimura F, Kagawa S, Shirakawa Y and Fujiwara
T: A novel synergistic effect of iron depletion on antiangiogenic
cancer therapy. Int J Cancer. 132:2705–2713. 2013. View Article : Google Scholar
|
|
21
|
Chen Z, Zhang D, Yue F, Zheng M, Kovacevic
Z and Richardson DR: The iron chelators Dp44mT and DFO inhibit
TGF-β-induced epithelial-mesenchymal transition via up-regulation
of N-Myc downstream-regulated gene 1 (NDRG1). J Biol Chem.
287:17016–17028. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Takaoka M, Harada H, Andl CD, Oyama K,
Naomoto Y, Dempsey KL, Klein-Szanto AJ, El-Deiry WS, Grimberg A and
Nakagawa H: Epidermal growth factor receptor regulates aberrant
expression of insulin-like growth factor-binding protein 3. Cancer
Res. 64:7711–7723. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yano S, Tazawa H, Hashimoto Y, Shirakawa
Y, Kuroda S, Nishizaki M, Kishimoto H, Uno F, Nagasaka T, Urata Y,
et al: A genetically engineered oncolytic adenovirus decoys and
lethally traps quiescent cancer stem-like cells in S/G2/M phases.
Clin Cancer Res. 19:6495–6505. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kalinowski DS and Richardson DR: The
evolution of iron chelators for the treatment of iron overload
disease and cancer. Pharmacol Rev. 57:547–583. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Miller LD, Coffman LG, Chou JW, Black MA,
Bergh J, D’Agostino R Jr, Torti SV and Torti FM: An iron regulatory
gene signature predicts outcome in breast cancer. Cancer Res.
71:6728–6737. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kikyo N, Suda M, Kikyo N, Hagiwara K,
Yasukawa K, Fujisawa M, Yazaki Y and Okabe T: Purification and
characterization of a cell growth factor from a human leukemia cell
line: Immunological identity with ferritin. Cancer Res. 54:268–271.
1994.PubMed/NCBI
|
|
27
|
Yu Y, Kovacevic Z and Richardson DR:
Tuning cell cycle regulation with an iron key. Cell Cycle.
6:1982–1994. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Nurtjahja-Tjendraputra E, Fu D, Phang JM
and Richardson DR: Iron chelation regulates cyclin D1 expression
via the proteasome: A link to iron deficiency-mediated growth
suppression. Blood. 109:4045–4054. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Chaston TB, Lovejoy DB, Watts RN and
Richardson DR: Examination of the antiproliferative activity of
iron chelators: Multiple cellular targets and the different
mechanism of action of triapine compared with desferrioxamine and
the potent pyridoxal isonicotinoyl hydrazone analogue 311. Clin
Cancer Res. 9:402–414. 2003.PubMed/NCBI
|
|
30
|
Boult J, Roberts K, Brookes MJ, Hughes S,
Bury JP, Cross SS, Anderson GJ, Spychal R, Iqbal T and Tselepis C:
Overexpression of cellular iron import proteins is associated with
malignant progression of esophageal adenocarcinoma. Clin Cancer
Res. 14:379–387. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Brookes MJ, Hughes S, Turner FE, Reynolds
G, Sharma N, Ismail T, Berx G, McKie AT, Hotchin N, Anderson GJ, et
al: Modulation of iron transport proteins in human colorectal
carcinogenesis. Gut. 55:1449–1460. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ford SJ, Obeidy P, Lovejoy DB, Bedford M,
Nichols L, Chadwick C, Tucker O, Lui GY, Kalinowski DS, Jansson PJ,
et al: Deferasirox (ICL670A) effectively inhibits oesophageal
cancer growth in vitro and in vivo. Br J Pharmacol. 168:1316–1328.
2013. View Article : Google Scholar :
|
|
33
|
Haass NK, Sproesser K, Nguyen TK,
Contractor R, Medina CA, Nathanson KL, Herlyn M and Smalley KS: The
mitogen-activated protein/extracellular signal-regulated kinase
kinase inhibitor AZD6244 (ARRY-142886) induces growth arrest in
melanoma cells and tumor regression when combined with docetaxel.
Clin Cancer Res. 14:230–239. 2008. View Article : Google Scholar : PubMed/NCBI
|
